Serous tumors of low malignant potential of the ovary-molecular pathology: Part 2

Virchows Archiv

Volumn 438, Issue 6, 2001, Pages 539-551

  Hauptmann, S ^a   Dietel, M ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Borderline tumors; Desmoplasia; Genetics; Hormone receptors; Inflammation; Oncogenes; Ovary; Serous tumors; Tumor suppressor genes; Tumors of low malignant potential

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 4; GELATINASE A; NERVE CELL ADHESION MOLECULE; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RAS PROTEIN;

ARTICLE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; KARYOTYPING; ONCOGENE NEU; ONCOGENE RAS; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

CADHERINS; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTADENOCARCINOMA, SEROUS; CYSTADENOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; DNA, NEOPLASM; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034927812     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280100435     Document Type: Article

References (147)

1. Estrogen receptor expression is a common feature of ovarian borderline tumors
2. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: Possible implications for the role of desmoplastic fibroblasts
3. Phenotypic plasticity of ovarium surface epithelium: Possible implications for ovarian carcinogenesis
4. Expression of 72 kilodalton type IV collagenase (gelatinase) in benign and malignant ovarian tumors
5. Immunohistochemical analysis of the p53 oncoprotein in paraffin sections using a series of novel monoclonal antibodies
6. Loss of epithelial cell differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E cadherin/β catenin complex in cells transformed with a temperature sensitive v-src gene
7. Chromosome aberrations in metastatic ovarian cancer: Relationship with abnormalities in primary tumors
8. Apoptosis and apoptosis-related proteins (Fas, Fas ligand, bcl-2, p53) in macrophages of human ovarian epithelial tumors
9. Over-expression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
10. Overexpression of p53 is not a feature of benign and early stage borderline epithelial ovarian tumors
11. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for determination of microsatellite instability in colorectal cancer
12. The human oncoprotein MDM 2 arrests the cell cycle: Elimination of its cell-cycle-inhibitory function induces tumorigenesis
13. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors
14. Comparison of mutations of Ki-ras and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors
15. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary
16. Expression of β1 and αvβ3 integrins in ovarian cancer
17. Human ovarian adenocarcinoma cells synthesize vitronectin and use it to organize their adhesion
18. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours
19. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients
20. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers
21. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: Clinicopathological correlations
22. The role of the HER-2/neu oncogene in gynecologic cancers
23. Borderline malignant serous tumors of the ovary maintained on extracellular matrix: Evidence for clonal evolution and invasive potential
24. K-ras mutations in nonmucinous ovarian epithelial tumors: Molecular analysis and clinicopathologic study of 144 patients
25. Control of angigogenesis in fibroblasts by p53 regulation of thrombospondin-1
26. Expression of Cadherins in benign, borderline, and malignant ovarian epithelial tumors: A clinicopathologic study of 60 cases
27. Analysis of CD44 expression in serous and mucinous borderline tumors of the ovary: Comparison with cystadenomas and overt carcinomas
28. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas
29. Expression of E-cadherin, α-catenin and β-catenin in normal ovarian surface epithelium and epithelial ovarian cancer
30. Karyotypic analysis of 32 epithelial ovarian tumors
31. 72-Kilodalton type IV collagenase, type IV collagen, and Ki67 antigen in serous tumors of the ovary: A clinicopathologic, immunohistochemical, and serological study
32. Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas
33. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: Comparison with serous cystadenomas and invasive serous carcinomas
34. Serous tumors of low malignant potential of the ovary: 1. Diagnostic pathology
35. Comparison of loss of heterocygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas
36. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma
37. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors
38. WAF1, a potential mediator of p53 tumor suppression
39. p53 and HER-2/neu overexpression in ovarian borderline tumors
40. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary
41. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: Evaluation of their respective prognostic significance by multivariate analysis
42. Biologic implications of the expression of vasular endothelial growth factor subtypes in ovarian carcinomas
43. Increased serum 72 kDa metalloproteinase in serous ovarian tumors: Comparison with Ca125
44. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors
45. Rates of Jewish Ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors
46. In serous ovarian neoplasms the frequency of Ki-ras mutations correlated with their malignant potential
47. Microsatellite analysis in serous tumors of the ovary
48. Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory cell infiltrates from tumor and ascites material
49. Expression and prognostic significance of Bcl-2 in ovarian tumors
50. Growth retardation and tumor inhibition by BRCA1
51. E cadherin and APC compete for the interaction with β-catenin and the cytoskeleton
52. p53 protein expression and DNA ploidy in common epithelial tumors of the ovary
53. Genetic analysis of benign, low-grade, and high-grade ovarian tumors
54. Cytogenetic studies of epithelial ovarian carcinoma
55. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms
56. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms
57. Micropapillary serus carcinoma of the ovary: An immunohistochemical and mutational analysis of p53
58. Proliferative serous tumors of the ovary. Histologic features and prognosis
59. Alterations of p53 in ovarian cancer: Its occurrence and maintenance in tumor progression
60. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors
61. Comparative cytogenetic and histologic studies on early malignant transformation in mesothelial tumors of the ovary
62. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer
63. Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status
64. Borderline tumors of the ovary: A clinico-pathologic and immunohistochemical study of 54 cases
65. p53 expression in ovarian borderline tumors and stage 1 carcinomas
66. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors
67. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor
68. Expression of αvβ3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas
69. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer
70. Comparison of p53 and MIB1 expression in benign and borderline areas of serous tumors
71. Overexpression and mutation of p53 in epithelial ovarian cancer
72. p63 and p73: Old members of a new family
73. Differential expression of apoptosis associated genes bax ynd bcl-2 in ovarian cancer
74. Extent of apoptosis in ovarian serous carcinoma: Relation mitotic and proliferative indices, p53 expression and survival
75. DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer
76. Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer
77. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy
78. Unusual features of serous neoplasms of low malignant potential during pregnancy
79. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the α2β1 integrin
80. Telomerase activity in ovarian tumors
81. Tumor necrosis factor and its receptors in human ovarian cancer
82. Expression and activity of MMPs and their regulators in ovarian cancer
83. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines
84. Analysis of p73 in human borderline and invasive ovarian tumors
85. Increased microvessel density in mucinous compared with malignant serous and benign tumors of the ovary
86. WAF1/CIP1 and MDM 2 characterizes serous borderline tumors
87. Vascular endothelial growth factor expression in early stage ovarian carcinoma
88. Simple numerical chromosomal aberrations in well-differentiated malignant epithelial tumors
89. Chromosomal aberrations in 35 primary ovarian carcinomas
90. Karyotypic characteristics of borderline malignant tumors of the ovary: Trisomy 12, trisomy 7, and r(1) as nonrandom features
91. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliaoms from lung adenocarcinomas
92. Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas
93. Fluorescence in situ hybridization analysis of trisomy 12 in ovarian tumors
94. Correspondence re: Boland CR et al.
95. Genetic alterations distinguish different types of ovarian tumors
96. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
97. Tumor infiltrating cells in human ovarian cancer
98. Detailed deletion mapping of chromosome 6q in borderline epithelial ovarian tumors
99. Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors
100. Her-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary
101. Prognostic significance of of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis
102. Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome
103. Trisomy 12 in various ovarian tumors of benign to low malignancy
104. Protooncogene amplification and tumor ploidy in human ovarian neoplasms
105. Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastase
106. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are induced by DNA damage
107. Expression of HER-2/neu protooncogene in serous ovarian neoplasms
108. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry
109. TP53 protein accumulation and gene mutation in relation to overexpresison of MDM 2 protein in ovarian borderline tumors and stage I carcinomas
110. Expression of α6 and β4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin
111. Studies of the HER-2/neu proto-oncogen in human breast and ovarian cancer
112. Tumor suppressor gene p53: Regulation and function
113. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors
114. pS2 and PAI-I in ovarian cancer: Correlation to pathohistological parameters
115. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinom
116. E-cadherin expression in human epithelial ovarian cancer and normal ovary
117. Frequent microsatellite instability in epithelial borderline ovarian tumors
118. Hepsin, a cell surface serin protease identified in hepatoma cells, is overexpressed in ovarian cancer
119. The matrix metalloprotease Pump-1 (MMP-7, Matrilysin): A candidate marker/target for ovarian cancer detection and treatment
120. The stratum corneum chymotryptoc enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells
121. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms
122. Numerical chromosome abnormalities associated with early clinical stages of gynecologic tumors
123. Simple numeric abnormalities as primary karyotype changes in ovarian carcinoma
124. Early involvement of 6q in surface epithelial ovarian tumors
125. Prognostic value of CD44 splice variant expression in ovarian cancer
126. Tumor-infiltrating lymphocytes from ovarian tumors of low malignant potential
127. Detection and clinical correlations of ras gene mutations in human ovarian tumors
128. Telomerase activity in benign and malignant epithelial ovarian tumors
129. Immunohistochemical analysis of bcl-2, byx, mcl-1, and bcl-X expression in ovarian surface epithelial tumors
130. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations
131. Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors
132. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumors
133. Expression of a homeobox gene (SIX5) in borderline ovarian tumors
134. Analysis of ovarian borderline tumors using comparative genomic hybridization and fluorescence in situ hybridization
135. Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: Influence of family history of ovarian cancer
136. RGD-containing peptides inhibit experimental peritoneal seeding of human ovarian cancer cells
137. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patients survival, and analysis of serum VEGF levels
138. Apoptotic index in ovarian carcinoma: Correlation with clinicopathologic factors and prognosis
139. Trisomy 12 and K-ras-2 amplification in human ovarian tumors
140. Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumors: Intratumoral molecular heterogeneity
141. MDM 2 oncogene as a novel target for human cancer therapy
142. Distinction of low grade from high grade ovarian carcinomas on the basis of losses of heterocygosity on chromosomes 3, 6 and 11 and HER-2/neu gene amplification
143. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone
144. Reduction of BRCA1 expression in sporadic ovarian cancer
145. Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms
146. Organization of type III collagen in benign and malignant ovarian tumors